1PGara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/ AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[-J]. J Am Coll Cardiol, 2013,61 (4) :485-510.
4Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans [J]- Drug Metab Dispos, 2007,35(7) : 1096-1104.
5Hagihara K, Kazui M, Kurihara A, et al. Biotransformation of prasugrel, a novel thienopyridine antiplatelet agent, to the pharmacologically active metabolite[-J]. Drug Metab Dispos, 2010,38(6) : 898-904.
6Hagihara K, Kurihara A, Kawai K, et al. Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats[-J]. Xenobiotica, 2007,37(7):788-801.
7Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes f-J]. N Engl J Med, 2007,357(20):2001-2015.
8Kurz DJ, Radovanovic D, Seifert B, et al. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry [-J]. Eur Heart J Acute Cardiovasc Care, 2015 Jan 22. [-Epub ahead of print].
9Chin CT, Roe MT, Fox KA, et al. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST- segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strategy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial[-J]. Am Heart J, 2010,160(1):16-22.
10Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization[-J 1. N Engl J Med, 2012, 367 ( 14 ) : 1297-1309.
二级参考文献26
1LevineGN,BatesER,BlankenshipJC,etal.2011 ACCF/AHA/SCAI Guideline for Percutaneous CoronaryIntervention:areportoftheAmericanCollegeofCardiologyFoundation/American Heart Association Task Force onPractice Guidelines and the Society for CardiovascularAngiographyandInterventions[J].Circulation,2011,124(23):e574-e651.
4WangTY,RobinsonLA,OuFS,etal.Dischargeantithromboticstrategies among patients with acute coronary syndromepreviouslyon warfarinanticoagulation:physicianpracticeintheCRUSADEregistry[J].Am HeartJ,2008,155(2):361-368.
6RuizNodarJM,MarinF,HurtadoJA,etal.Anticoagulantand antiplatelet therapy use in 426 patients with atrialfibrillation undergoing percutaneous coronary interventionandstentimplantation implicationsfor bleeding risk andprognosis[J].JAm CollCardiol,2008,51(8):818-825.
7RuizNodarJM,MarinF,SanchezPayaJ,etal.Efficacyandsafety of drugeluting stent use in patients with atrialfibrillation[J].EurHeartJ,2009,30(8):932-939.
8SambolaA,FerreiraGonzalezI,AngelJ,etal.Therapeuticstrategiesaftercoronarystentinginchronicallyanticoagulatedpatients:the MUSICA study[J].Heart,2009,95(18):1483-1488.
